Sun Pharma shares jump over 4% after $11.75 billion Organon deal

Sun Pharma has agreed to buy Organon in an all-cash $11.75 billion deal, including debt. The takeover expands its reach in women's health and marks a sharper global push.

In Short

• Boards of both companies have cleared the all-cash transaction already
• Organon brings businesses across women's health, biosimilars and established medicines
• The acquisition expands Sun Pharma's footprint across about 140 countries

Sun Pharmaceutical Industries (Sun Pharma) has announced the biggest acquisition in its history, agreeing to buy US-based Organon & Co. in an all-cash deal valued at $11.75 billion, including debt. The transaction is the largest deal ever in Indian pharma and among the biggest overseas takeovers by an Indian company.

The pharma company's share price jumped over 4.60% to Rs 1694.40 at around 9:19 am.

The company will pay $14 per share for Organon, offering shareholders a premium over the stock’s previous closing price. The deal has been approved by the boards of both companies and is expected to close in early 2027, subject to regulatory and shareholder approvals.

Why this matters

The acquisition gives Sun Pharma immediate scale in key global markets and expands its portfolio beyond its traditional strengths in generics and specialty medicines.

Organon was spun off from Merck & Co. in 2021 and has built businesses in women’s health, biosimilars and established medicines. It operates in around 140 countries, giving Sun Pharma a much wider commercial reach.

For Sun Pharma, the deal strengthens its position in segments expected to see long-term demand growth, particularly women’s health.

Sun Pharma has long been India’s largest drugmaker, with a strong domestic business and growing overseas presence. But the Organon acquisition signals a sharper move toward becoming a diversified global pharmaceutical company.

The company, like many peers, has been navigating pricing pressure in the US generics market. Expanding into branded products and specialty segments can help improve margins and reduce dependence on commoditised businesses.

The deal will be funded through a mix of internal cash and borrowings, making leverage and post-merger integration key areas of focus for investors.

Markets will watch how smoothly Sun Pharma absorbs Organon’s operations, manages debt, and unlocks growth from the acquired portfolio.

This is more than an acquisition. With its biggest-ever deal, Sun Pharma is signalling that it wants a much larger role in global healthcare markets.

If executed well, the Organon buyout could become a defining moment in the company’s evolution from India’s top pharma company to a broader multinational player.

- Ends